Literature DB >> 21084006

Lack of evidence of neoantigen formation in different batches of a double-virus inactivated factor VIII concentrate manufactured in Argentina.

Hugo Guglielmone, Federico Farias, Cristian Moya, David Navarro, María Susana Vitali.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21084006      PMCID： PMC3096866          DOI： 10.2450/2010.0042-10

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

1.  Inhibitor development.

Authors:  J Astermark; S Lacroix-Desmazes; M T Reding
Journal:  Haemophilia       Date:  2008-07       Impact factor: 4.287

Review 2.  Neoantigens and antibodies to factor VIII.

Authors:  C V Prowse; I R MacGregor
Journal:  Blood Rev       Date:  1998-06       Impact factor: 8.250

3.  Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

Authors:  Samantha C Gouw; Johanna G van der Bom; Günter Auerswald; Carmen Escuriola Ettinghausen; Ulf Tedgård; H Marijke van den Berg
Journal:  Blood       Date:  2007-01-11       Impact factor: 22.113

Review 4.  Risk of inhibitors in haemophilia and the type of factor replacement.

Authors:  Jenny Goudemand; Yves Laurian; Thierry Calvez
Journal:  Curr Opin Hematol       Date:  2006-09       Impact factor: 3.284

Review 5.  Back to the future: a recent history of haemophilia treatment.

Authors:  P M Mannucci
Journal:  Haemophilia       Date:  2008-07       Impact factor: 4.287
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.